Search clinical trials for: JNJ-39393406

Total 870 results

Janssen Research & Development, LLC

Recruiting

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Adenocarcinoma | Prostatic Neoplasms

United States
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (YATAGARASU)

Salivary Gland Neoplasms

Japan
Janssen Research & Development, LLC

Completed

Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants

Healthy Participants

Belgium
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

Hepatitis C, Chronic

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers

Healthy | Pharmacokinetics | Drug Interactions
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers

Healthy
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

Diabetes Mellitus, Type 2

United States
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Irritable Bowel Syndrome

United States, Canada, United Kingdom
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

Respiratory Syncytial Viruses

United States, Belgium, Canada, Hungary, Japan, Poland
Janssen Sciences Ireland UC

Completed

Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

Respiratory Syncytial Virus Infections

United Kingdom
Janssen-Cilag, S.A.

Completed

An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

Depression

Mexico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants

Healthy

Belgium
Peter MacCallum Cancer Centre, Australia
Janssen, LP

Recruiting

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL)

Extramedullary Myeloma

Australia
Janssen Research & Development, LLC

Withdrawn

Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus (STEP)

Metapneumovirus

Netherlands, United States, France, Taiwan, Korea, Republic of, Australia, Japan, Spain, Malaysia, Russian Federation, Sweden, Poland, Bulgaria, Argentina, Brazil, Ukraine
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Neoplasms | Myelodysplastic Syndromes | Non-Hodgkin Lymphoma | Solid Tumor, Adult

United States, Spain, Israel, Germany, Canada
Janssen Sciences Ireland UC

Completed

A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

Hepatitis B, Chronic

Belgium, Germany, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Brazil
Janssen Research & Development, LLC

Terminated

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Depressive Disorder, Major

United States, Spain, Italy, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of 14C JNJ-67953964 in Healthy Adult Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

Healthy

Netherlands
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Irritable Bowel Syndrome

United States, Canada, Puerto Rico, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

Healthy

United States
Janssen Pharmaceutica N.V., Belgium

Active, not recruiting

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

Bipolar Disorder

United States, Spain, Poland, Canada
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants

Healthy

Japan
University of California, San Francisco
Janssen Pharmaceuticals

Active, not recruiting

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer (PILLAR)

Castration-Resistant Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

Respiratory Syncytial Virus

Canada, United Kingdom, Spain, Brazil, Sweden, Poland, Australia, Finland
Janssen Research & Development, LLC

Completed

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease (TRIDENT)

Crohn Disease

United States, France, Poland, Ukraine, Germany, Belgium, Bulgaria, Romania, Japan, Canada, Korea, Republic of, Russian Federation, Hungary, United Kingdom
Janssen Research & Development, LLC
Genentech, Inc.

Completed

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX)

Carcinoma, Non-Small-Cell Lung

France, United States, Spain, Hungary, Poland
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

Respiratory Tract Infections | Respiratory Syncytial Viruses

United Kingdom, Finland, United States
Actelion

Completed

A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study (SOMBRERO)

Hypertension, Pulmonary

Taiwan, Korea, Republic of, Belarus, India, Romania, Ukraine
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)

Hepatitis B, Chronic

Taiwan, Poland, Japan, New Zealand
Janssen Research & Development, LLC

Active, not recruiting

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Japan, Taiwan, Spain, United States, Argentina, Ukraine, Germany, Poland, Bulgaria, Colombia, South Africa, Hungary
Janssen Research & Development, LLC

Completed

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

Sjogren's Syndrome

United States, Germany, Netherlands, Japan, Taiwan, Italy, France, Spain, Poland, Portugal
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Prostate Cancer

Taiwan, Korea, Republic of
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

Prostatic Neoplasms

Italy, Russian Federation, Brazil, Portugal, Belgium, Spain, United States, Austria, Hungary, Turkey, Germany, Australia, Poland, Mexico, Finland, Slovakia, Lebanon, Czechia, Denmark, Jordan, Sweden
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

Healthy

United States
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Insomnia Disorders

Belgium, United States, Germany, Poland, Japan, France
Actelion

Active, not recruiting

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension (SALTO)

Hypertension, Pulmonary

United States, Belgium, Korea, Republic of, Taiwan, Canada, Israel, Russian Federation, Switzerland, France, Thailand, Poland, China, Hungary, Spain, Turkey, Belarus, Germany, Serbia, Bulgaria, Brazil, Mexico, Italy, Sweden, Ireland, Ma... and more
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Influenza A

United States, France, Korea, Republic of, Taiwan, China, India, Argentina, Israel, Thailand, Vietnam, Hungary, Germany, South Africa, Spain, Turkey, Belgium, Brazil, Canada, Mexico, New Zealand, Bulgaria, Peru, Malaysia, Italy, Estonia, ... and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

France, Germany
Rahul Aggarwal
Janssen Scientific Affairs, LLC

Active, not recruiting

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Prostate Cancer | Small Cell Carcinoma | Small Cell Neuroendocrine Carcinoma

United States
Janssen Research & Development, LLC
The Scripps Research Institute

Withdrawn

Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults

Alcoholism

United States
Janssen Research & Development, LLC

Completed

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

Pain | Osteoarthritis

United States, Spain, Poland, United Kingdom
Janssen Research & Development, LLC

Completed

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

Pain | Osteoarthritis

United States, Poland, Spain, Canada, Belgium, Netherlands, Czechia, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Prostatic Neoplasms

United States

3

Subscribe